Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited announced that its subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, has obtained a drug registration certificate for Clarithromycin for Suspension from the National Medical Products Administration. This development marks a significant step for the company as it aligns with pharmaceutical production quality management standards, potentially enhancing its market position and expanding its product offerings in the prescription drug market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in the People’s Republic of China. It is involved in the production of various pharmaceutical products, with a focus on prescription drugs. The company operates through its subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, which recently received a drug registration certificate for Clarithromycin for Suspension.
Average Trading Volume: 8,369,606
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.52B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.